Dr. Patrick N. Shaklee obtained his Ph.D. in Biochemistry from the University of Illinois (USA) in 1985 under the direction of Professor H. Edward Conrad. Following postdoctoral work at the University of Wisconsin, Dr. Shaklee was Assistant Professor of Biochemistry at the University of North Texas from 1989-1992. From 1992-1994, he was Scientist III at Glycomed Incorporated, and from 1994-2000 was Senior Research Scientist at Scientific Protein Laboratories. From 2000 thru 2008, Dr. Shaklee has been President and Director of Technical Operations at BioCascade Incorporated in Arlington, Wisconsin.
Dr. Shaklee’s career has focused on development of chemical, physical, and bioanalytical tools for glycosaminoglycan analysis, with a particular focus on heparin and the chondroitin sulfates. During graduate work, Dr. Shaklee developed chemical disaccharide analysis techniques for the chondroitin sulfates and keratan sulfate, demonstrated that low levels of 2-sulfated glucuronic acid were present in heparin, and subsequently discovered a specific glucurono-2-sulfatase present in human and avian lysosomal extracts. Later, in conjunction with James Knobloch, he showed the general utility and applicability of multi-angle laser light scattering to LMW-heparin molecular weight determinations. Finally, since 1999, Dr. Shaklee has been an active member of the WHO Working Group on Harmonized Methods for Unfractionated Heparin Potency Determination, and served from 2000-2007 on the USP Expert Committee on Blood and Blood Products.
Rossix is a family owned, family operated company devoted to hemostasis research and diagnostics. The company represents the experience of more than 30 years of development work in the field.
Rossix provides guidance to and reagents for functional methods in coagulation testing and the vast majority of our customers are pharmaceutical companies and academic bioscience laboratories.
We can help your company with method development, contract analysis and manufacturing of tailor-made reagents, all with emphasis on providing flexible solutions to meet your specific needs.
Craig M. Jackson is president of Hemosaga Diagnostics Corp., a start-up company in San Diego. Prior to founding Hemosaga Diagnostics, he operated a San Diego, based consulting practice. Jackson has served as president and director of research and development for Reagents Applications Inc. and as scientific director for the American Red Cross Blood Services (Detroit) where he was also an adjunct professor of biochemistry at Wayne State University. He was a professor of biological chemistry and an associate professor of internal medicine at Washington University School of Medicine (St. Louis) prior to joining the American Red Cross. He has been a visiting professor at Kyushu University (Fukuoka, Japan) and the University of Hawaii. Jackson is a member of the editorial advisory board for IVD Technology magazine. He has written more than 70 original papers, contributed to more than 30 textbooks, writes regularly for both professional and trade journals, and holds several patents. He is a member of Working Group 1 of the Joint Committee for Traceability in Laboratory Medicine (JCTLM), an organization founded by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), the Bureau International des Poids et Mesures (BIPM), and the International Laboratory Accreditation Cooperation (ILAC). JCTLM provides the mechanism by which the European Union,s In Vitro Device Directive requirement for traceability can be met. On the JCTLM, Jackson has led the team that has developed the quality system. Jackson received a BS degree from Washington State University (Pullman, WA) and a PhD from the University of Washington (Seattle). He is a fellow of the National Academy of Clinical Biochemistry (Washington, DC) and also a fellow of the American Association for the Advancement of Science (Washington, DC).